|
Lymphoma, T-Cell, Cutaneous
|
0.010 |
Biomarker
|
disease |
BEFREE |
Resistant CTCL exhibited high levels of histone acetylation, which correlated with increased expression of 338 genes (FDR < 0·05), including some novel to CTCL: BIRC5 (anti-apoptotic); RRM2 (cell cycle); TXNDC5, GSTM1 (redox); and CXCR4, LAIR2 (cell adhesion/migration).
|
31358475 |
2019 |
|
Malignant neoplasm of mouth
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have developed a novel siRNA-based therapeutic strategy targeting BCL2 and BIRC5 for oral cancer.
|
31744202 |
2019 |
|
Lip and Oral Cavity Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we have developed a novel siRNA-based therapeutic strategy targeting BCL2 and BIRC5 for oral cancer.
|
31744202 |
2019 |
|
Leukocyte adhesion deficiency type 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Then, using BIRC5 as a candidate, the prognostic value in LAD and TN adenocarcinomas was verified by the Kaplan-Meier plotter and The Cancer Genome Atlas (TCGA) database, respectively.
|
31093306 |
2019 |
|
Recurrent tumor
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We found that BIRC5 expression levels were increased in GC tissues as compared with the adjacent normal tissues, and acted as an independent prognostic factor of tumor recurrence in patients with GC.
|
31663299 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
This platform includes: 1) defining BIRC5 as an early PDAC-upregulated gene and utilizing an enhanced BIRC5 super-promoter to drive expression of dual Gaussia luciferase (GLuc) and sr39 thymidine kinase (sr39TK) reporter genes exponentially and specifically in PDAC; 2) utilizing a genetically-engineered AAV<sub>2</sub><sup>RGD</sup> to ensure targeted delivery of GLuc and sr39TK specifically to PDAC; 3) using serologic GLuc and sr39TK microPET/CT imaging to detect and localize minute human PDAC in mice.
|
31059751 |
2019 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to adjacent tissues, osteosarcoma tissues had significantly depressed miR-218 expression and elevated BIRC5 expression (p<0.05). miR-21 targeted 3'-UTR of BIRC5 to suppress its expression.
|
30402837 |
2018 |
|
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent studies indicate that survivin (BIRC5) is sensitive to the existence of previous ischemic heart disease, since it is activated in the process of tissue repair and angiogenesis.
|
30581346 |
2018 |
|
Esophageal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/Akt signaling pathway.
|
30127937 |
2018 |
|
Sleep Apnea, Obstructive
|
0.010 |
Biomarker
|
disease |
BEFREE |
Survivin (Birc5) is an anti-apoptotic protein which inhibits Type 1 inflammation; however, this molecule has not been investigated in OSA.
|
29740686 |
2018 |
|
Malignant neoplasm of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/Akt signaling pathway.
|
30127937 |
2018 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to adjacent tissues, osteosarcoma tissues had significantly depressed miR-218 expression and elevated BIRC5 expression (p<0.05). miR-21 targeted 3'-UTR of BIRC5 to suppress its expression.
|
30402837 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to adjacent tissues, osteosarcoma tissues had significantly depressed miR-218 expression and elevated BIRC5 expression (p<0.05). miR-21 targeted 3'-UTR of BIRC5 to suppress its expression.
|
30402837 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, panobinostat-treatment enhanced α-tubulin-acetylation, decreased the expression of survival-related genes Bcl-XL and BIRC5/survivin, and was associated with induction of ER stress and apoptosis in IPF-fibroblasts.
|
30481203 |
2018 |
|
HIV-1 infection
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative mass spectrometry-based proteomics, we showed that HIV-1 infection activated cellular survival programs that were governed by BIRC5, a molecular inhibitor of cell apoptosis that is frequently overexpressed in malignant cells.
|
29802019 |
2018 |
|
Malignant neoplasm of penis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition to the potential driver genes herein described, shorter overall survival was associated with BIRC5 and DNMT3B overexpression (log-rank test, P = 0.026 and P = 0.002, respectively) highlighting its potential as novel prognostic marker for penile cancer.
|
28751665 |
2017 |
|
Osteoglophonic dwarfism
|
0.010 |
Biomarker
|
disease |
BEFREE |
To determine the potential roles of PPARγ in brain microvascular endothelial (bEnd.3) cells during cerebral ischemia and the relationship between PPARγ and BIRC5, a cerebral ischemia model was established with bEnd.3 cells cells by oxygen‑glucose deprivation (OGD) treatment.
|
29039513 |
2017 |
|
MICROPHTHALMIA, SYNDROMIC 7
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, BIRC5 was important for MLS survival because a strong inhibitory effect was seen at low concentration using the survivin inhibitor YM155, and siRNA for BIRC5 decreased cell viability.
|
28654818 |
2017 |
|
Penis carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition to the potential driver genes herein described, shorter overall survival was associated with BIRC5 and DNMT3B overexpression (log-rank test, P = 0.026 and P = 0.002, respectively) highlighting its potential as novel prognostic marker for penile cancer.
|
28751665 |
2017 |
|
Adult Penile Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition to the potential driver genes herein described, shorter overall survival was associated with BIRC5 and DNMT3B overexpression (log-rank test, P = 0.026 and P = 0.002, respectively) highlighting its potential as novel prognostic marker for penile cancer.
|
28751665 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because microRNAs are powerful post-transcriptional regulators of gene expression, we used bioinformatic analyses to search for microRNAs that could potentially target BIRC5 in the setting of bladder cancer.
|
27978829 |
2016 |
|
Biliary stricture
|
0.010 |
Biomarker
|
disease |
BEFREE |
The measurement of the mRNA expression levels of CDH3, IGF2BP3, and BIRC5 by real-time polymerase chain reaction combined with cytology was useful for the differentiation of malignant and benign biliary strictures in brush cytology specimens.
|
27399126 |
2016 |
|
Progressive Neoplastic Disease
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
BIRC5 upregulation was linked to stable disease (SD) or progressive disease (PD).
|
26537080 |
2016 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because microRNAs are powerful post-transcriptional regulators of gene expression, we used bioinformatic analyses to search for microRNAs that could potentially target BIRC5 in the setting of bladder cancer.
|
27978829 |
2016 |
|
Progressive cGVHD
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
BIRC5 upregulation was linked to stable disease (SD) or progressive disease (PD).
|
26537080 |
2016 |